Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50908
Name myelodysplastic syndrome
Definition A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myelodysplastic syndrome

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Azacitidine myelodysplastic syndrome not applicable detail...
Unknown unknown Rigosertib Sodium myelodysplastic syndrome no benefit detail...
ASXL1 mutant N/A myelodysplastic syndrome not applicable detail...
RUNX1 mutant N/A myelodysplastic syndrome not applicable detail...
ETV6 mutant N/A myelodysplastic syndrome not applicable detail...
SF3B1 mutant N/A myelodysplastic syndrome not applicable detail...
Unknown unknown Guadecitabine myelodysplastic syndrome not applicable detail...
SRSF2 mutant N/A myelodysplastic syndrome not applicable detail...
U2AF1 mutant N/A myelodysplastic syndrome not applicable detail...
Unknown unknown Decitabine myelodysplastic syndrome not applicable detail...
SETBP1 mutant N/A myelodysplastic syndrome not applicable detail...
EZH2 mutant N/A myelodysplastic syndrome not applicable detail...
ZRSR2 mutant N/A myelodysplastic syndrome not applicable detail...
STAG2 mutant N/A myelodysplastic syndrome not applicable detail...
SF3B1 E622X N/A myelodysplastic syndrome not applicable detail...
SF3B1 Y623X N/A myelodysplastic syndrome not applicable detail...
SRSF2 P95X N/A myelodysplastic syndrome not applicable detail...
SF3B1 R625X N/A myelodysplastic syndrome not applicable detail...
SF3B1 N626X N/A myelodysplastic syndrome not applicable detail...
SF3B1 H662X N/A myelodysplastic syndrome not applicable detail...
SF3B1 T663X N/A myelodysplastic syndrome not applicable detail...
SF3B1 K666X N/A myelodysplastic syndrome not applicable detail...
SF3B1 K700E N/A myelodysplastic syndrome not applicable detail...
SF3B1 I704X N/A myelodysplastic syndrome not applicable detail...
SF3B1 G740X N/A myelodysplastic syndrome not applicable detail...
SF3B1 G742X N/A myelodysplastic syndrome not applicable detail...
SF3B1 D781X N/A myelodysplastic syndrome not applicable detail...
U2AF1 S34X N/A myelodysplastic syndrome not applicable detail...
U2AF1 Q157X N/A myelodysplastic syndrome not applicable detail...
NRAS G12X N/A myelodysplastic syndrome not applicable detail...
NRAS G13X N/A myelodysplastic syndrome not applicable detail...
NRAS Q61X N/A myelodysplastic syndrome not applicable detail...
IDH2 R140Q N/A myelodysplastic syndrome not applicable detail...
IDH2 R172X N/A myelodysplastic syndrome not applicable detail...
BCOR mutant N/A myelodysplastic syndrome not applicable detail...
Unknown unknown Cytarabine + Glasdegib myelodysplastic syndrome not applicable detail...
Unknown unknown Cytarabine + Daunorubicin + Glasdegib myelodysplastic syndrome not applicable detail...
Unknown unknown FF-10501-01 myelodysplastic syndrome not applicable detail...
NPM1 W288fs N/A myelodysplastic syndrome not applicable detail...
FLT3 exon 14 ins N/A myelodysplastic syndrome not applicable detail...
FLT3 D835X N/A myelodysplastic syndrome not applicable detail...
GATA2 mutant N/A myelodysplastic syndrome not applicable detail...
Unknown unknown Danazol myelodysplastic syndrome not applicable detail...
Unknown unknown Azacitidine + Hu5F9-G4 myelodysplastic syndrome not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00801489 Phase II Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias Recruiting USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting USA 0
NCT01211457 Phase Ib/II Sapacitabine + Venetoclax Decitabine + Sapacitabine Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes Unknown status USA 0
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting USA 0
NCT01773395 Phase II Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus GVAX vs. Placebo for MDS/AML After Allo HSCT Active, not recruiting USA 0
NCT01804101 Phase I CPX-351 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Active, not recruiting USA 0
NCT01892371 Phase Ib/II Azacitidine + Quizartinib Cytarabine + Quizartinib Quizartinib With Azacitidine or Cytarabine in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Active, not recruiting USA 0
NCT01898793 Phase Ib/II Aldesleukin + Cyclophosphamide + Fludarabine ALT-803 + Cyclophosphamide + Fludarabine Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Recruiting USA 0
NCT01915498 Phase I Enasidenib Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation Active, not recruiting USA 1
NCT02019069 Phase II CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02115295 Phase II Cladribine + Cytarabine + Idarubicin Midostaurin Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting USA 0
NCT02117219 Phase I Azacitidine + Durvalumab Phase 1 Study to Evaluate MEDI4736 in MDS Completed USA 3
NCT02117297 Phase II Gemtuzumab ozogamicin SCT Plus Immune Therapy in Average Risk AML/MDS Recruiting USA 0
NCT02193958 Phase Ib/II FF-10501-01 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02221310 Phase II Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS Recruiting USA 0
NCT02228525 Phase II Selinexor Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes Active, not recruiting USA 0
NCT02240706 Phase II BI 836858 Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes Terminated USA 1
NCT02250937 Phase II Cladribine Busulfan Busulfan + Venetoclax Fludarabine Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT02267863 Phase I APTO-253 A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS Recruiting USA 0
NCT02269579 Phase II CPX-351 Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment Withdrawn USA 0
NCT02273102 Phase I Tranylcypromine + Tretinoin Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) Completed USA 0
NCT02281084 Phase II Azacitidine Azacitidine + Durvalumab Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes Active, not recruiting USA 8
NCT02367456 Phase Ib/II Azacitidine + Glasdegib A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients Active, not recruiting USA | CAN 4
NCT02462252 Phase II anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Completed USA 0
NCT02472145 Phase III Decitabine Decitabine + Talacotuzumab An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed USA 13
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting USA 0
NCT02487459 Phase I BPX-501 Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT02494167 Phase I MultiTAA-specific T cells Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Recruiting USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02508870 Phase I Azacitidine Atezolizumab A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Completed USA 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Recruiting USA 0
NCT02530463 Phase II Nivolumab Azacitidine Ipilimumab Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) Recruiting USA 0
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT02553941 Phase I Azacitidine + Ibrutinib Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT02556931 Phase II Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Active, not recruiting USA 0
NCT02562443 Phase III Rigosertib Sodium Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE) Active, not recruiting USA | CAN 20
NCT02564536 Phase I Decitabine + Pacritinib Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Withdrawn 0
NCT02576301 Phase Ib/II Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Unknown status USA 0
NCT02598661 Phase III Imetelstat Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Recruiting USA | CAN 15
NCT02610777 Phase II Azacitidine MLN4924 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Active, not recruiting USA | CAN 10
NCT02641002 Phase I CC-90002 A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT02666950 Phase II Adavosertib Cytarabine WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02676323 Phase Ib/II Cytarabine + Fludarabine + Leucovorin + Panobinostat Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Terminated USA 0
NCT02677922 Phase Ib/II Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Active, not recruiting USA | CAN 10
NCT02683395 Phase I PLX51107 A Study of PLX51107 in Advanced Malignancies Terminated USA 0
NCT02684162 Phase II Guadecitabine SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) Recruiting USA 0
NCT02719574 Phase I Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation Recruiting USA | CAN 7
NCT02721875 Phase I Azacitidine Volasertib Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes Terminated 1
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting USA 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting USA 0
NCT02728050 Phase Ib/II Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT02743611 Phase I Rimiducid BPX-701 Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms Active, not recruiting USA 0
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Terminated USA 0
NCT02756572 Phase I Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT02775903 Phase II Azacitidine Azacitidine + Durvalumab An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) Active, not recruiting USA | CAN 10
NCT02779777 Phase II Tipifarnib Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Terminated USA 0
NCT02786485 Phase I Rimiducid BPX-501 Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn 0
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting USA 0
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed USA 0
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Recruiting USA 0
NCT02807558 Phase II Azacitidine + Tamibarotene Tamibarotene A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Active, not recruiting USA 1
NCT02829840 Phase Ib/II Azacitidine + Ponatinib Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Withdrawn 0
NCT02841540 Phase I H3B-8800 A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Active, not recruiting USA 3
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Active, not recruiting USA 0
NCT02848001 Phase I CC-90009 A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes Recruiting USA | CAN 4
NCT02890329 Phase I Decitabine + Ipilimumab Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Recruiting USA 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Recruiting USA 0
NCT02907359 Phase III Cytarabine Guadecitabine Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Completed USA | CAN 12
NCT02909972 Phase I ALRN-6924 + Cytarabine ALRN-6924 Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed USA 0
NCT02923986 Phase Ib/II BP1001 + Dasatinib Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS Withdrawn USA 0
NCT02935361 Phase Ib/II Atezolizumab + Guadecitabine Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Recruiting USA 0
NCT02936752 Phase I Entinostat + Pembrolizumab Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure Active, not recruiting USA 0
NCT02942290 Phase II Azacitidine Azacitidine + Venetoclax A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS) Active, not recruiting USA | CAN 5
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting USA 0
NCT02966782 Phase I Azacitidine + Venetoclax Venetoclax A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure Active, not recruiting USA 2
NCT02979366 Phase I MIK665 Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome Completed USA 3
NCT02981914 Phase 0 Pembrolizumab Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Recruiting USA 0
NCT02989844 Phase II ALT-803 QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT Recruiting USA 0
NCT03011034 Phase II Talacotuzumab Daratumumab Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment Active, not recruiting USA 5
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting USA 1
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Active, not recruiting USA 0
NCT03047993 Phase Ib/II Azacitidine + Telaglenastat Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Recruiting USA 0
NCT03066648 Phase I Decitabine + Spartalizumab Decitabine + Sabatolimab + Spartalizumab Decitabine + Sabatolimab Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Recruiting USA 7
NCT03067571 Phase II Daratumumab Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03069469 Phase I DCC-3014 Study of DCC-3014 in Patients With Advanced Malignancies Recruiting USA | CAN 5
NCT03072043 Phase Ib/II APR-246 + Azacitidine Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Active, not recruiting USA 0
NCT03074006 Phase Ib/II TEW 7197 Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS) Active, not recruiting USA 0
NCT03075826 Phase II Guadecitabine A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Active, not recruiting USA 0
NCT03092674 Phase II Cytarabine + Decitabine Azacitidine + Midostaurin Decitabine Azacitidine + Nivolumab Azacitidine Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03094637 Phase II Azacitidine + Pembrolizumab Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS) Recruiting USA 0
NCT03113643 Phase I Azacitidine + Tagraxofusp-erzs + Venetoclax Azacitidine + Tagraxofusp-erzs SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting USA 0
NCT03128034 Phase Ib/II Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Recruiting USA 0
NCT03151304 Phase II Azacitidine + Pracinostat Azacitidine A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes Completed USA 0
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT03187288 Phase I CFI-400945 A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting CAN 0
NCT03214562 Phase Ib/II Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT03214666 Phase Ib/II GTB-3550 TriKE GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies Recruiting USA 0
NCT03238248 Phase II Azacitidine + MLN4924 Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors Recruiting USA 0
NCT03248479 Phase I Azacitidine + Hu5F9-G4 Hu5F9-G4 Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies Recruiting USA 1
NCT03268954 Phase III Azacitidine + MLN4924 Azacitidine Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) Active, not recruiting USA | CAN 18
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Recruiting USA 0
NCT03306264 Phase III Decitabine Decitabine and Cedazuridine Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML Recruiting USA | CAN 8
NCT03326310 Phase I Azacitidine + Selumetinib Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia Recruiting USA 0
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting USA 0
NCT03358719 Phase I Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03359460 Phase I Ibrutinib + Lenalidomide Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome Recruiting USA 0
NCT03383575 Phase II Azacitidine + Enasidenib Enasidenib Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Recruiting USA 0
NCT03386513 Phase I IMGN632 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting USA 3
NCT03393611 Phase I anti-thymocyte globulin + Fludarabine + Melphalan CPX-351 CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT03397173 Phase II Azacitidine + Vitamin C TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid Active, not recruiting USA 0
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Recruiting USA 0
NCT03404726 Phase I BAY2402234 A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies Recruiting USA 1
NCT03417154 Phase II Cyclophosphamide + Nivolumab Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS Suspended USA 0
NCT03459859 Phase I Cytarabine + MLN4924 Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS Recruiting USA 0
NCT03465540 Phase I AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies Active, not recruiting USA 5
NCT03471260 Phase Ib/II Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies Recruiting USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03515512 Phase I Enasidenib IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting USA 0
NCT03516591 Phase I AMV-564 A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes Active, not recruiting USA 0
NCT03537599 Phase Ib/II Daratumumab Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Recruiting USA 0
NCT03564821 Phase I Ivosidenib IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting USA 0
NCT03572764 Phase I CPX-351 CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome Recruiting USA 0
NCT03573310 Phase I JNJ-64619178 A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS Recruiting USA | CAN 3
NCT03594955 Phase Ib/II SAR440234 First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome Recruiting USA 1
NCT03603964 Phase II Guadecitabine Guadecitabine Extension Study Active, not recruiting USA | CAN 7
NCT03613532 Phase I Busulfan + Fludarabine + Venetoclax Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN Recruiting USA 0
NCT03614728 Phase I Azacitidine + GSK3326595 GSK3326595 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Recruiting USA | CAN 0
NCT03661307 Phase Ib/II Decitabine + Quizartinib + Venetoclax Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Recruiting USA 0
NCT03672539 Phase I Gemtuzumab ozogamicin CPX-351 + Gemtuzumab ozogamicin Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03699475 Phase II BPX-501 + Rimiducid Cyclophosphamide Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE) Terminated USA 0
NCT03735446 Phase I Cytarabine + Etoposide + Mitoxantrone + Prexasertib Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial Terminated USA 0
NCT03745716 Phase III APR-246 + Azacitidine Azacitidine APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) Active, not recruiting USA 1
NCT03746041 Phase I Abaloparatide + Bevacizumab A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes Recruiting USA 0
NCT03770429 Phase I AZD6738 AZD6738 for Patients With Progressive MDS or CMML Recruiting USA 0
NCT03772925 Phase I Belinostat + MLN4924 Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT03787498 Phase I PLX2853 A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03814005 Phase I Azacitidine + MLN4924 A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment Recruiting USA 1
NCT03843528 Phase I Azacitidine + Vorinostat Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT03884829 Phase I CYC140 A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Recruiting USA 0
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Active, not recruiting USA 0
NCT03886662 Phase Ib/II LB-100 A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Recruiting USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Recruiting USA 0
NCT03896269 Phase I CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting USA 0
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Recruiting CAN 0
NCT03915379 Phase I JNJ-67571244 A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Recruiting USA 2
NCT03927261 Phase I PRGN-3006 PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS Recruiting USA 0
NCT03929211 Phase Ib/II CPI-613 + Hydroxychloroquine CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome Not yet recruiting USA 0
NCT03931291 Phase II APR-246 + Azacitidine APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant Recruiting USA 0
NCT03932643 Phase I ONC201 ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant Recruiting USA 0
NCT03940352 Phase I HDM201 + Venetoclax HDM201 + Sabatolimab HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Recruiting USA 7
NCT03946670 Phase II Decitabine + Sabatolimab Azacitidine Azacitidine + Sabatolimab Decitabine A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). Active, not recruiting USA | CAN 15
NCT03953898 Phase II Olaparib Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Recruiting USA 0
NCT03957876 Phase II CPX-351 CPX-351 Therapy for MDS After Hypomethylating Agent Failure Recruiting USA 0
NCT03969446 Phase I Decitabine + Pembrolizumab Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Recruiting USA 0
NCT03974217 Phase I Talazoparib Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Recruiting USA 0
NCT04013880 Phase Ib/II Decitabine and Cedazuridine + Olutasidenib ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Withdrawn 0
NCT04021368 Phase I SEL120-34A SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Recruiting USA 0
NCT04022785 Phase I Azacitidine + PLX51107 PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT04047641 Phase II Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04055844 Phase II Decitabine + Ruxolitinib Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Recruiting USA 0
NCT04092179 Phase Ib/II Enasidenib + Venetoclax Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Recruiting CAN 0
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Recruiting USA 0
NCT04109482 Phase Ib/II Cyclophosphamide + Decitabine + Fludarabine + MB-102 Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. Recruiting USA 0
NCT04128020 Phase I Azacitidine + Nivolumab Nivolumab Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Withdrawn 0
NCT04128748 Phase Ib/II CPX-351 + Quizartinib Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04139434 Phase I LP-108 Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT04140487 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Recruiting USA 0
NCT04160052 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Recruiting USA 0
NCT04187703 Phase I Azacitidine + Decitabine 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies Recruiting USA 0
NCT04227847 Phase I SEA-CD70 A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Recruiting USA 0
NCT04239157 Phase II Azacitidine + Canakinumab Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04243785 Phase I BTX-A51 A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04245397 Phase I SX-682 SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy Recruiting USA 0
NCT04264806 Phase II ARGX-110 + Azacitidine Azacitidine A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) Not yet recruiting USA 11
NCT04266301 Phase III Azacitidine Azacitidine + Sabatolimab Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2) Recruiting USA 26
NCT04278768 Phase I CA-4948 An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT04284228 Phase Ib/II Cyclophosphamide + Fludarabine + NEXI-001 T Cells Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Recruiting USA 0
NCT04313881 Phase III Azacitidine Azacitidine + Hu5F9-G4 Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE) Recruiting USA 1
NCT04361058 Phase I Nivolumab Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide Recruiting USA 0
NCT04401748 Phase III Azacitidine + Venetoclax Azacitidine Safety And Efficacy Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Complete Remission and Overall Survival In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) Recruiting USA | CAN 21
NCT04417517 Phase Ib/II ALX148 + Azacitidine A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) Recruiting USA 0
NCT04487106 Phase II Azacitidine + Trametinib + Venetoclax Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04493138 Phase Ib/II Azacitidine + Quizartinib Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Recruiting USA 0
NCT04493164 Phase II CPX-351 + Ivosidenib Ivosidenib CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Not yet recruiting USA 0
NCT04543305 Phase I PRT1419 A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Recruiting USA 0
NCT04550442 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04582864 Phase II Flotetuzumab Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Not yet recruiting USA 0
NCT04655755 Phase Ib/II Decitabine and Cedazuridine + Venetoclax Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Not yet recruiting USA 0
NCT04708054 Phase II Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Not yet recruiting USA 0
NCT04734990 Phase Ib/II Azacitidine + Seclidemstat Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Not yet recruiting USA 0